Stimcell Energetics (STME) Net Cash Flow Growth (1y) (2012 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -564.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -31.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -394.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 57.36% |
| 10 | Stimcell Energetics | - | - | - | -34.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -34.55% |
| Nov 30, 2025 | 197.53% |
| Aug 31, 2025 | 64.47% |
| May 31, 2025 | 121.15% |
| Feb 28, 2025 | -147.27% |
| Nov 30, 2024 | 138.16% |
| Aug 31, 2024 | 43.21% |
| May 31, 2024 | -139.93% |
| Feb 29, 2024 | 630.79% |
| Nov 30, 2023 | -501.18% |
| Aug 31, 2023 | -175.38% |
| May 31, 2023 | 1,500.08% |
| Feb 28, 2023 | -58.91% |
| Nov 30, 2022 | 133.81% |
| Aug 31, 2022 | -134.34% |
| May 31, 2022 | -7.85% |
| Feb 28, 2022 | -504.06% |
| Nov 30, 2021 | 73.46% |
| Aug 31, 2021 | -43.53% |
| May 31, 2021 | 91.12% |
| Feb 28, 2021 | 101.04% |
| Nov 30, 2020 | -25.76% |
| Aug 31, 2020 | -74.37% |
| May 31, 2020 | 1.61% |
| Feb 29, 2020 | -249.21% |
| Nov 30, 2019 | -1,597.85% |
| Aug 31, 2019 | 5,446.56% |
| May 31, 2019 | -351.29% |
| Feb 28, 2019 | 226.28% |
| Nov 30, 2018 | 102.38% |
| Aug 31, 2018 | -97.94% |
| May 31, 2018 | -125.55% |
| Feb 28, 2018 | 22.60% |
| Nov 30, 2017 | -372.55% |
| Aug 31, 2017 | 2,349.12% |
| May 31, 2017 | 273.99% |
| May 31, 2013 | 75.01% |
| Feb 28, 2013 | -121.10% |
| May 31, 2012 | 50.26% |